-
公开(公告)号：US09927429B2
公开(公告)日：2018-03-27
申请号：US14411496
申请日：2013-07-08
Applicant: Randox Laboratories Ltd.
Inventor： Maria Zellner , Ellen Umlauf
IPC: G01N33/53 , G01N33/566 , C07K16/00 , G01N33/68
CPC classification number: G01N33/5308 , G01N33/6896 , G01N2333/4712 , G01N2800/2814 , G01N2800/2821
Abstract: The present invention provides an in vitro method to aid the diagnosis of Alzheimer's disease (AD) or Mild Cognitive Impairment (MCI), comprising determining the level of expression of one or more tropomyosin isoform(s) corresponding to P09493-3 and/or P09493-1 in a patient's sample. A kit comprising probes that bind to tropomyosin isoforms P09493-3 and P09493-1 is also provided.
-
公开(公告)号：US09892229B2
公开(公告)日：2018-02-13
申请号：US14435991
申请日：2013-10-16
Applicant: RANDOX LABORATORIES LTD.
Inventor： Mark William Ruddock , Cherith N. Reid , Kate E. Williamson , Frank Emmert-Streib , John V. Lamont , Peter Fitzgerald
CPC classification number: G06F19/18 , G01N33/57407 , G01N33/57484 , G01N2333/4737 , G01N2333/4742 , G01N2333/475 , G01N2333/485 , G01N2333/523 , G01N2333/525 , G01N2333/5406 , G01N2333/5412 , G01N2333/5421 , G01N2333/545 , G01N2333/55 , G01N2333/70578 , G01N2333/70596 , G01N2333/7151 , G01N2333/7452 , G01N2333/928 , G01N2333/96433 , G01N2333/96494 , G01N2333/988 , G01N2400/00 , G06F19/00 , G06F19/24 , G16H50/30
Abstract: The invention provides a method of defining the likelihood of a subject having bladder cancer, comprising the steps of: (A) assessing the subject's likelihood of having bladder cancer by: i. identifying at least one sub-population group appropriate to the subject; ii. determining the level of one or more biomarkers selected according to the sub-population group in a sample obtained from the subject; iii. inputting each of the biomarker values into an algorithm to produce an output value; and iv. correlating the output value with the likelihood of the subject having bladder cancer, wherein the sub-population group is selected according to smoking habits, gender, presence/absence of stone disease, history of benign prostate enlargement (BPE) or prescription of anti-hypertensive, anti-platelet and/or anti-ulcer medication, and (B) determining the subject's stratified risk level of serious disease by: v. determining the level of one or more biomarkers specific for one or more risk classifiers defined using Random Forest Classifiers (RFC), logistic regression or another appropriate systems biology or statistical approach in a sample obtained from the subject, vi. inputting each of the biomarker values into an algorithm or algorithms to produce an output value; and vii. correlating the output value with a stratified risk level of underlying serious disease, wherein the likelihood of having bladder cancer is combined with the stratified risk level of having serious disease, wherein the risk of having bladder cancer and/or serious disease is categorized as: high-risk bladder cancer requiring immediate cystoscopy; low-risk bladder cancer requiring urgent cystoscopy; high-risk control requiring close evaluation and further investigation; or low-risk control requiring primary care monitoring.
-
公开(公告)号：US20170348692A1
公开(公告)日：2017-12-07
申请号：US15534460
申请日：2015-12-14
Applicant: Randox Laboratories Ltd.
Inventor： Stuart JACKSON , Ivan MCCONNELL , John LAMONT , Peter FITZGERALD , Marc WHARRY
CPC classification number: B01L9/52 , B01L3/508 , B01L2200/0689 , B01L2200/142 , B01L2300/042 , B01L2300/044 , B01L2300/045 , B01L2300/047 , B01L2300/0636 , B01L2300/0832 , B01L2300/161 , B65B7/2871 , C12M23/38
Abstract: The present invention is directed to a cap for a biochip storage well. The cap comprises a resilient sealant layer capable, under the application of pressure, of forming a vapour-proof seal with a line contact interface formation extending around the perimeter of a biochip storage well.An assay assembly comprising the cap of the invention and a biochip storage is disclosed. Methods of sealing a biochip storage well using a cap of the invention are also disclosed.
-
公开(公告)号：US20170212117A1
公开(公告)日：2017-07-27
申请号：US15502711
申请日：2015-08-06
Applicant: Randox Laboratories Limited
Inventor： Clifford Taggart , Sinead Weldon , Chris Scott
IPC: G01N33/573 , C07K16/40 , C07K5/113
CPC classification number: G01N33/573 , C07K5/1021 , C07K16/38 , C07K16/40 , C07K2317/34 , G01N2333/96425 , G01N2800/26
Abstract: The invention relates to a novel antibody which binds to C-SLPI selected from the group consisting of SEQ ID NOs: 3 and 4.
-
公开(公告)号：US09612237B2
公开(公告)日：2017-04-04
申请号：US14186650
申请日：2014-02-21
Applicant: Randox Laboratories Limited
Inventor： Philip Lowry , Elouard Benchikh , Ivan McConnell , Peter Fitzgerald
CPC classification number: G01N33/5308 , C07K16/44 , C07K2317/33
Abstract: The invention provides novel antibodies which specifically bind to the methylphenidate metabolite, ritalinic acid, enabling an immunoassay that can detect methylphenidate in biological samples for an extended period following its ingestion. The invention also describes novel conjugates and kits incorporating the antibodies.
-
Patent Agency Ranking
公开(公告)号：US20170030917A1
公开(公告)日：2017-02-02
申请号：US15302849
申请日：2015-04-02
Applicant: Randox Laboratories Ltd.
Inventor： Alex Chacko , Ivan McConnell , Peter Fitzgerald , John V. Lamont
IPC: G01N33/574
CPC classification number: G01N33/57484 , A61P35/00 , A61P35/04 , C07K14/54 , G01N33/53 , G01N33/57423 , G01N33/6869 , G01N2333/54 , G01N2800/52
Abstract: The present invention describes methods for screening for cancer in a subject, by measuring the level of dimeric IL-18 in a sample obtained from the subject, and comparing that level with the level in a normal control sample.The present invention also describes an assay for screening for cancer in a subject, by measuring the level of dimeric IL-18 in a sample obtained from the subject, whereby an elevated level of dimeric IL-18 is indicative of cancer.
Abstract translation: 本发明还描述了通过测量从受试者获得的样品中的二聚体IL-18的水平来筛选受试者中的癌症的测定，由此提高的二聚体IL-18水平是癌症的指示。
-
公开(公告)号：US20170003308A1
公开(公告)日：2017-01-05
申请号：US15200558
申请日：2016-07-01
Applicant: Randox Laboratories Ltd
Inventor： Ivan McConnell , Philip Lowry , Elouard Benchikh , Peter Fitzgerald
IPC: G01N33/94 , C07C225/20 , C07C229/14 , C07K16/44 , C07K14/435
CPC classification number: G01N33/94 , C07C225/20 , C07C229/14 , C07K14/43504 , C07K16/44 , C07K2317/33 , C07K2317/92
Abstract: Components for enabling immunodetection of methoxetamine are described including immunogens, haptens, antibodies and kits.
Abstract translation: 描述了用于实现甲氧胺的免疫检测的组分，包括免疫原，半抗原，抗体和试剂盒。
-
公开(公告)号：US20160245800A1
公开(公告)日：2016-08-25
申请号：US15042095
申请日：2016-02-11
Applicant: Randox Laboratories Ltd.
Inventor： Elouard Benchik , Ivan McConnell , Peter FitzGerald , Philip Lowry
CPC classification number: G01N33/5308 , C07K16/44 , C07K2317/14 , C07K2317/33 , C07K2317/92 , G01N33/9486
Abstract: Antibodies, immunoassay methods and kits for the detection and determination of 3,4,-dichloro-N-[(1-(dimethylamino)cyclohexyl)methyl]benzamide and 3,4,-dichloro-N-[(1-(methylamino)cyclohexyl)methyl]benzamide, as well as the precursory immunogens, are described.
Abstract translation: 用于检测和测定3,4， - 二氯-N - [（1-（二甲基氨基）环己基）甲基]苯甲酰胺和3,4， - 二氯-N - [（1-（甲基氨基）苯基）苯甲酰胺的抗体，免疫测定方法和试剂盒， 环己基）甲基]苯甲酰胺，以及前体免疫原。
-
公开(公告)号：US20160229824A1
公开(公告)日：2016-08-11
申请号：US15130137
申请日：2016-04-15
Applicant: RANDOX LABORATORIES LIMITED
Inventor： Elouard BENCHIKH , Ivan McConnell , Philip Lowry , Peter Fitzgerald
IPC: C07D295/155 , G01N33/53 , C07K14/47 , C07K14/765 , C07K16/44
CPC classification number: C07D295/155 , C07D241/04 , C07D295/096 , C07K14/47 , C07K14/765 , C07K16/44 , C07K2317/76 , G01N33/5308
Abstract: The current invention describes novel immunogens which are used in the production of novel antibodies with unique binding properties in that they cross-react with a variety of phenylpiperazine derivatives. These antibodies enable methods and kits to detect and/or determine phenylpiperazine derivatives (for example mCPP, TFMPP and MeOPP) in an in vitro sample which are advantageous over currently available analytical methods in terms of cost, ease of use, speed and sensitivity.
Abstract translation: 本发明描述了新型免疫原，其用于生产具有独特结合特性的新型抗体，因为它们与各种苯基哌嗪衍生物交叉反应。 这些抗体使得方法和试剂盒能够在体外样品中检测和/或测定苯基哌嗪衍生物（例如mCPP，TFMPP和MeOPP），这在成本，易用性，速度和灵敏度方面优于现有的分析方法。
-
公开(公告)号：US20160139147A1
公开(公告)日：2016-05-19
申请号：US14895724
申请日：2014-06-04
Applicant: RANDOX LABORATORIES
Inventor： Ivan McConnell , John Lamont , Peter Fitzgerald , Konstantinos Makris
IPC: G01N33/68
Abstract: The present invention provides a method of aiding the differential diagnosis of haemorrhagic stroke, ischemic stroke and a transient ischemic attack in a patient who has suffered or is suffering a stroke. The method comprises: (i) determining the concentration of the biomarkers VCAM-1, GFAP and CRP in an ex vivo sample obtained from the patient; and (ii) establishing the statistical significance of the concentration of the biomarkers. Optionally, the method further comprises steps of (iii) determining the concentration of the biomarkers IL-6 and sTNFR1 in an ex vivo sample obtained from the patient; (iv) determining the gender of the patient; and (v) establishing the statistical significance of the concentration of the five biomarkers, in conjunction with the patient's gender. The present invention also provides substrates comprising probes for VCAM-1, GFAP and CRP for use in a method for aiding the differential diagnosis of stroke.
Abstract translation: 本发明提供了一种在遭受或正在卒中的患者中帮助出血性中风，缺血性卒中和短暂性脑缺血发作的鉴别诊断的方法。 该方法包括：（i）确定从患者获得的离体样品中生物标志物VCAM-1，GFAP和CRP的浓度; 和（ii）确定生物标志物浓度的统计学意义。 任选地，所述方法还包括以下步骤：（iii）确定从患者获得的离体样品中生物标志物IL-6和sTNFR1的浓度; （iv）确定患者的性别; 和（v）结合病人的性别确定五种生物标志物的浓度的统计学显着性。 本发明还提供了用于VCAM-1，GFAP和CRP的探针的底物，用于帮助中风鉴别诊断的方法。
-
-
-
-
-
-
-
-
-
Search Results
138
records
(took 0.021 seconds)
